strategic second recap and discuss on to of us ladies a are and morning gentlemen. Good we that XXXX joining you for Company. quarter initiatives as working this to morning the Thank the
price. like would what Before to stock believe our meaningful comment I on begin our formal we is presentation, a to overhang we
a a Company delivery Over years, the and Company the being transitioned to as specialty of have pharma from drug past couple Company. reformulation we
business perform We FTXXX not we guidance, didn't our reduce anticipated shareholders. that clearly for had From managed delayed created frustration NOCTIVA a adequately occasion, to on expectations. particularly being long-term as our our on have we having have, pediatric to acquiring shareholders and
original was to competition. As long-term to sustained approved given generate we But even unapproved better originally The never and entrance to cash have cannot anticipated. streams intended the intention the be strategy. produced strategy flow, said, always cash of a the we products than new have revenue excellent was the be
the allowed certainly impact have two over us We years few But Company an into products the meaningful to have seen transform very these last the with of that. opportunities. large entity
growing always that a from we will strive for protect have information our as divulging that position a we make progress decisions. allows too Company, could to investors recognize our to them that shareholders compromise we as While much information good competitive need
As information previously such, we disclosed. on today's call not will provide additional
So above with moving into in our revenue, hospital million products. QX, from we primarily in top-line consensus three $XX came
the fourth still sterile at first end year part product, the this a are file in sometime XXXX. injectable, to of our or planning We of hospital also
As with position you a an as the a improved safety FDA a process and we existing result. formulation potential with have gaining hopeful may the uncovered of preferred are problem approval recall, product,
we long-term a NOCTIVA products FTXXX. of solid we deeper but these flow expectations, like be recognize to I of will our Albeit we us. or either to clinical FTXXX. shortly are the dive to our strategy sources timely our complete on inspire we hopefully growth are We and dive trial ability right in basis components piece bit a take Mike quite close in around regarding hospital approval, XXXX. Assuming to the product the the will provide to continue across today's for to margin additional cash high product to a into initiatives this not the that in this study market. kept and the important are such some have going ongoing vest the and expect revenue call, and some seeing enrollment longer meaningful resulting revenue that study taken has where study. and Kanan to bring transparency into as begin dynamics On overall
release where frank, months enrolled have you to-date. few For those know ago, who patients very trial About have XX XX% we of Europe we that you began may enrolled. to the seen be this approximately are our been morning, in
where majority have a of the most for we for operational have a been So patients part the little the Canada only the and over U.S. from come year.
there As many a like running. delays unique getting cetera. issues change. FTXXX, licensing et like sites Saw we having delayed the approvals of middle IRB more sites some were and commonplace with DEA were in engaging U.S. procedural the disclosed, in Others previously up the to
second As a be next we will U.S. new sites of adding the over result, year we U.S. last operational the sites since quarter planned the of months. only in have had our majority and few seven initially
the for such are Some competing studies capacity, been various DEA participation of as had sites unable outset, time to licensing reasons, we these issues. for join but at vetted at and that even
investigators. up new new markets pleased new are and are to now and come us patient We they able onboard to open tools,
exposure drug that XX-months and The been to at taken are enrollment. able have to oxybate. least patients without that two of the We we include study. should of around for second X.X past the to have of use accelerate to than number sodium a our prior secure patient our other with cannot compromising half underway limited of more a past the protocol has weeks dose use spot gram the have a to than parameters were last Recently, initiatives enrollment change more
sort be the around through it for and people it change these additive. their contacting may We sodium have patients ineligible to XXX been they in and collect other of reasons. requirements initially provide don't identified are to excluded context have the we as process previously We tool new on certainly these previously majority and of excluded who screening mostly patients over them our relates meet the necessarily history be But oxybate. online expect were to to should some asked of
patients Additionally, now of past discussed we them number took clinical expect potential effort, into that the this have new the and criteria they upon patients help new oxybate. process. of patients from across investigators the use our patient are believe we a they that be referral ongoing currently sodium with change to and eligible some the this new use all meet To meet have we when support we to review into who may identify would have also screening may last potential dependent criteria, Also, program database a future sources sites past the screen. clinical our funnel implementing to now
seven sodium not expected next available. U.S. to the to Australia oxybate XX In currently will have we in sites open the addition over is opening in weeks where two new the sites
Australian covered will third very Australia four good coming have We onboard key After there. deal will all the in the have a of that next months and geographies be additive. sometime will research, site think be Having all site in in planned. licenses a for We approvals, we import to believe are of six taking by the those randomization seeing required XX%. these and QX our underway are export regulatory as are being initiatives hold initiations exceeded recently we QX applications currently and we received
benefit between I sites total, list both have are now that which of sites the to implementing you active site we best be constantly seen have retention. new sites, practices active productivity. also over and I observed now expected expect These of XX watch closures we up sites early XX the QX, that our clinicaltrials.gov nine see new website not old. have many next months are and We In will weeks said will investors few a and screening the news to over the we months recruitment, the to on likely XXXX, coming few assessing and earlier. relating over last as where and from to
also to date positive field update Many made investors for on primary amendment. feel the protocol we provide this XXXX clinicaltrials.gov. September patients We when new randomization. we So ability their noticed required were about have to of our completion
to around However, feel it the to We frustration study taking is firsthand placeholder we set yet end simply this a are prepared not time many an understand the enroll, is date. and confident product already potential and is reiterate product complete to this belief trial awareness. but amount an This will going we that impressive and our changer. have of it be are a game
That high already oxybate. over Our patients form online an that people one-time XXXX out XXXX albeit already sodium by level is excludes screening nightly tool our interested investigational of extremely people. been bulk the filled in has
the with within suggesting of debilitating nightly why data, in may that patients puzzle orphan of the a manner the provide some a year. piece drop to large non-compliant their out dose XX% are for physician for product interest is we good almost with who disease available. recent patients of start as Given second qualitative a market and XX% or options recent In preference options indication were than to We greater a that so have once of with patients. to research, early is few nightly low-sodium believe available on a even come for when XX% generics average this learn twice
enrolling will trial. patients objective for awareness near-term be continue the Our raising in FTXXX to
resulted albeit slower XXXX base, strategic to why XXXX $X our over over address launch. reception to in major demand dispensed expectations $XX NOCTIVA. $XX from since unique a in uptick, to changed yet million revenue to initiative a From our million. Regarding positive we from million want and growth second has to $XX a seen have I and minute here they million little prescriptions prescribers take
our have How portion the mix larger to-date. of for revenue Part-D to coverage the we higher who assumed. tracking been commercial originally of have at translates largest of Furthermore prescriptions. While not virtually over are levels is that and yet assistant on assistance be is influx yet than where provided completed, than and preferred co-pay we is out with to has patients, of XXXX non-existent. seen with seen Part-D patients based What we July month support originally commercial high-deductible pocket commercial a expected, the plans
net a has at benefitted the in be the their still they important of dramatically numerous alike the launch confirmed through who and NOCTIVA revenues. it patients time waiting believe improve patients on physicians looking that at just that indicative Because we first this, by patients. have of of on turned feedback in seen and and in seen getting improving. This of creation. are XX early is secure XX% from treatment treatment. of symptoms has to some our now but overall, Barring This product. a value Part-D our this than revenue are on success gross-to-net think Although have and is patients program specialty have make rate term reason to more night decreasing and we to while metrics because outset long of been have sure pharmacy aren't also belief our this, want the we mix for many is months, are cash every out This hit these over the coverage XX% has and potential certainly this directly positive of patient night received XX the resulted we to of traction from we first have investors this on to we
up a of in being prevalent associated first increases are than women, a the It's our just and in more coming co-morbidities. market in and Nocturia the a treat generating We level diagnosed the here the XX% less coverage gone success which is just and no no Nocturia with in a reflective patients plan of We high [ph] we for months initiating market and months, is the Nocturia. we Each and and equally falls as we The of to Part-D. XX% months NOCTIVA, feel of trial in from is treating highlight particularly XX likelihood are men few need reached education approved. two physicians next market. as particularly team, include is Urology improving new importance an access, greatly number short have about months and this nine of interest the indication presence from solution. short with day, to up over release months especially to have This unaided of than and We considering publications And innovation NOCTIVA believe a about proving by of We of and few progress XX suffered fractures. keys representative in condition the where worth as the promotion. product, Community noise both March in treated. the brand the night. the the awakenings never just serious has is independently, of awareness XX million no of and importance a good made increasing before the In patients that many experience as Nocturia two per to condition to no over over and to around suffering in to less XX%, branded [relevance]
payer without NDC analog over have Another six two in covered many lives blocks contracts, is critical XX% despite Even to-date, any filled get positions prescriptions no with Furthermore, of factor days. we get we contracted all XX launch some and Part-D formulary commercial still coverage. first retail our covered covered Right with coverage have patients. preferred success seen filled secured brand Part-D major preferred typical payers. the product approximately products in month XXX new outperformed access million has now, with or
quarter, seeing. have expect to now to coverage These expect mix distributed of are much month coverage in future in the size given and to experience our wins. look September XX been block catalyst six be XX to as commercials really Part-D trade XXXX revenue To going initiation we NDC the ultimately Part-D serve for full our have we able we next recognize to in we we and first a we that launch physician the support improve over samples to especially as market, only which Part-D for a full forward prescriptions. in factor, over are the months, have to critical XXXX preferred As we how first ends as exited contracts,
made In addition in have here decision Canada. in to the seek our launch U.S., we the approval to
initiated primary as have urology United franchise. important NOCTIVA we well addition, States Nocturnal the additional formulations. These In early to in as development expand for are or enuresis new and opportunities bedwetting, our
approved, meaningful have don't taking fluid believe updates. We a marketing not advantages on relates briefly more This believe launched are to touch we after standpoint, yet of world on and share intake we but restrictions we that From with me specifically real patient very to provide medication. strict to experience. recently will will it both compete before the those product As these as have we leads the the NOCTIVA. reflective
into to Ferring’s be. insight no but have is we timing, regardless, We prepared launch will job be and our
Lastly as party are and the proceedings Ferring. you to we legal know, now between Serenity
will indications or into investors revenue and estimates our overall have XX in this how update comment $XXX was market to appropriately. anywhere plus potential. million million matters only much and potential want per publicly the maintained further in pursue increases emphasize can exceeding on we NOCTIVA at expand we marketable one litigation next to reported to the revenue other to upon that quarter over million opportunity any not the and and We considered will our might franchise peak grow that competition we cash urology. We $XXX I and from year market $XXX depending numbers investment execution. These be and capitalized the create Overall, from years. synergistic securities strategic XX always our strategic our in-licensing second of acquisition June are well within
keep We we area they initiatives are arise. committed as to this and you of apprised growing in will strategic
I joined and turning our to that our Mike Glass, I comments program who team. Pharmaceuticals with of results Company and we board quarter's of session. COO election number former meeting members our Before want update will concludes Palczuk, review over turn two you AstraZeneca's before units. to who of have currently over the Kanan Linda Mike. my Pantheon to previously also executive, Q&A led to the current of wrap program in CEO certified some a Kanan, I financial up just shareholders new the the commercial know final July, let and That Mike Geoff Sancilio at Verrica and and
